Belin, Catherine
Devic, Perrine
Ayrignac, Xavier
Dos Santos, Amélie
Paix, Adrien
Sirven-Villaros, Lila
Simard, Claire
Lamure, Sylvain
Gastinne, Thomas
Ursu, Renata
Berger, Colette
Platon, Laura
Tessoulin, Benoît
Azoulay, Elie
Wallet, Florent
Thieblemont, Catherine
Bachy, Emmanuel
Cartron, Guillaume
Laplaud, David A.
Carpentier, Antoine F.
Article History
Received: 10 July 2020
Accepted: 20 October 2020
First Online: 4 November 2020
Competing interests
: C. Belin: Honoraria Gilead; G. Cartron: Consultant for Celgene, Roche. Honoraria: Sanofi, Abbvie, Jansen, Celgene, Roche, Gilead; E. Azoulay: Honoraria from Pfizer, Gilead, Baxter, Alexion and Ablynx; A. F Carpentier: Consultant for BMS. Honoraria from Gilead; C. Thieblemont: Consultant/advisory board member for Amgen Celgene Jazz Pharmaceutical Kyte Novartis Servier Roche – Financial support (institution) : Roche, Hospira, Celgene, Novartis; D. Laplaud: honoraria: Biogen, Roche, Novartis, MedDay, Sanofi, Celgene, MSD, Teva, and Merck. C. Simard: Honoraria Gilead; P. Devic: Honoraria Gilead, Novartis, Pfizer. F. Wallet: Consultant for Gilead kite, Novartis. Honoraria: Jazz pharmaceuticals; E. Bachy: Honoraria: Gilead, Novartis, Roche, Amgen, Janssen, Sanofi, and Abbvie; Consultancy: Roche, Celgene, Gilead.